Halozyme and Acumen ink collaboration for Enhanze technology

6 November 2023
halozyme_logo_big

Halozyme Therapeutics (Nasdaq: HALO) today announced a global collaboration and non-exclusive license agreement with fellow US biotech Acumen Pharmaceuticals (Nasdaq: ABOS), following which the former’s shares dipped 1.2% to $35.62 and Acumen’s stock fell 1.1% to $2.14.

The deal will provide Acumen with access to Halozyme's Enhanze drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery, for a single target.

Acumen intends to explore the potential use of Enhanze for ACU193, Acumen's clinical-stage monoclonal antibody (MAb) candidate to target amyloid-β oligomers (AβOs) for the treatment of early Alzheimer's disease (AD).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology